128 related articles for article (PubMed ID: 20428938)
61. Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Inda MA; Blok EJ; Kuppen PJK; Charehbili A; den Biezen-Timmermans EC; van Brussel A; Fruytier SE; Meershoek-Klein Kranenbarg E; Kloet S; van der Burg B; Martens JWM; Sims AH; Turnbull AK; Dixon JM; Verhaegh W; Kroep JR; van de Velde CJH; van de Stolpe A
Mol Cancer Ther; 2020 Feb; 19(2):680-689. PubMed ID: 31727690
[TBL] [Abstract][Full Text] [Related]
62. Absence of the K303R estrogen receptor α mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Ghimenti C; Mello-Grand M; Regolo L; Zambelli A; Chiorino G
Exp Ther Med; 2010 Nov; 1(6):939-942. PubMed ID: 22993622
[TBL] [Abstract][Full Text] [Related]
63. A transcription/translation-based gene signature predicts resistance to chemotherapy in breast cancer.
He DX; Xia YD; Gu XT; Jin J; Ma X
J Pharm Biomed Anal; 2015 Jan; 102():500-8. PubMed ID: 25459950
[TBL] [Abstract][Full Text] [Related]
64. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
de Cremoux P; Valet F; Gentien D; Lehmann-Che J; Scott V; Tran-Perennou C; Barbaroux C; Servant N; Vacher S; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Asselain B; Marty M; Spyratos F
BMC Cancer; 2011 Jun; 11():215. PubMed ID: 21631949
[TBL] [Abstract][Full Text] [Related]
65. Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer.
Stone A; Valdes-Mora F; Clark SJ
Epigenomics; 2013 Dec; 5(6):595-8. PubMed ID: 24283871
[No Abstract] [Full Text] [Related]
66. [Molecular prognostic and predictive markers of breast cancer treatment].
de Cremoux P
Bull Cancer; 2010 Nov; 97(11):1297-304. PubMed ID: 21047718
[TBL] [Abstract][Full Text] [Related]
67. Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics.
Penrod NM; Moore JH
BMC Syst Biol; 2014 Feb; 8():12. PubMed ID: 24495353
[TBL] [Abstract][Full Text] [Related]
68. An update on chemotherapy and tumor gene expression profiles in breast cancer.
Tan SH; Lee SC
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1083-113. PubMed ID: 22681410
[TBL] [Abstract][Full Text] [Related]
69. Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer.
Ternès N; Arnedos M; Koscielny S; Michiels S; Lanoy E
Curr Opin Oncol; 2014 Nov; 26(6):576-83. PubMed ID: 25210869
[TBL] [Abstract][Full Text] [Related]
70. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
Buchholz TA; Stivers DN; Stec J; Ayers M; Clark E; Bolt A; Sahin AA; Symmans WF; Hess KR; Kuerer HM; Valero V; Hortobagyi GN; Pusztai L
Cancer J; 2002; 8(6):461-8. PubMed ID: 12500855
[TBL] [Abstract][Full Text] [Related]
71. Journal expresses concern about validity of breast cancer study.
Mayor S
BMJ; 2010 Jul; 341():c4056. PubMed ID: 20660514
[No Abstract] [Full Text] [Related]
72. Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot.
Wu Y; Gong X; Wang K; Yu C; Qiu J; Zhang S; Hu Y; Hu K
Comb Chem High Throughput Screen; 2023; 26(5):1030-1041. PubMed ID: 35718967
[TBL] [Abstract][Full Text] [Related]
73. Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.
Pearce DA; Arthur LM; Turnbull AK; Renshaw L; Sabine VS; Thomas JS; Bartlett JM; Dixon JM; Sims AH
Sci Rep; 2016 Jul; 6():29434. PubMed ID: 27384960
[TBL] [Abstract][Full Text] [Related]
74. Breast cancer prognostication and prediction in the postgenomic era.
Lønning PE; Knappskog S; Staalesen V; Chrisanthar R; Lillehaug JR
Ann Oncol; 2007 Aug; 18(8):1293-306. PubMed ID: 17317675
[TBL] [Abstract][Full Text] [Related]
75. A Novel Mathematical Approach for Analysis of Integrated Cell-Patient Data Uncovers a 6-Gene Signature Linked to Endocrine Therapy Resistance.
Parga-Pazos M; Cusimano N; Rábano M; Akhmatskaya E; Vivanco MD
Lab Invest; 2024 Jan; 104(1):100286. PubMed ID: 37951307
[TBL] [Abstract][Full Text] [Related]
76. Approaches towards expression profiling the response to treatment.
Sims AH; Bartlett JM
Breast Cancer Res; 2008; 10(6):115. PubMed ID: 19144210
[TBL] [Abstract][Full Text] [Related]
77. Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer.
Miller WR
Expert Rev Endocrinol Metab; 2011 May; 6(3):345-357. PubMed ID: 30754108
[TBL] [Abstract][Full Text] [Related]
78. Obviating the Need for Serial Biopsies Through Random Assignment.
Sweis RF; Ratain MJ
J Clin Oncol; 2017 Jan; 35(2):260. PubMed ID: 28056195
[No Abstract] [Full Text] [Related]
79. Radiation recall reaction with anastrozole treatment in breast cancer.
Haydaroglu A; Sert F; Kazandi AC; Unal I
Pract Radiat Oncol; 2012; 2(4):e65-e68. PubMed ID: 24674187
[No Abstract] [Full Text] [Related]
80. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
